Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$34.51
neg -0.10
-0.30%
Today's Range: 34.49 - 34.75 | PFE Avg Daily Volume: 44,438,400
Last Update: 05/31/16 - 12:37 PM EDT
Volume: 9,092,842
YTD Performance: 7.22%
Open: $34.67
Previous Close: $34.61
52 Week Range: $28.25 - $36.46
Oustanding Shares: 6,064,849,361
Market Cap: 209,904,436,384
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 8 7 7
Moderate Buy 0 0 0 0
Hold 6 5 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.80 1.77 1.60 1.60
Latest Dividend: 0.30
Latest Dividend Yield: 3.47%
Dividend Ex-Date: 05/11/16
Price Earnings Ratio: 14.98
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
14.98 28.40 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.49% 0.90% 19.18%
GROWTH 12 Mo 3 Yr CAGR
Revenue -1.50 -0.20 -0.06
Net Income -23.80 -0.30 -0.10
EPS -21.70 -0.40 -0.17
Earnings for PFE:
EBITDA 18.13B
Revenue 48.85B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.63 $0.63 $2.46 $2.64
Number of Analysts 6 4 8 9
High Estimate $0.69 $0.66 $2.51 $2.79
Low Estimate $0.58 $0.61 $2.40 $2.45
Prior Year $0.56 $0.60 $2.20 $2.46
Growth Rate (Year over Year) 11.61% 4.58% 11.65% 7.66%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
Peter Lynch and other market legends would love these names.
I prefer a bullish synthetic call.
Investors watching 13F portfolioS for investment clues are reminded to look at a fund's whole portfolio before following too closely in its footsteps
It is hard to see much growth in the market overall, until earnings growth returns.
Investors rushed to the Palo Alto, Calif.-based drugmaker on news of Pfizer's generous takeover valuation.
The expected legal deluge will be manageable thanks to JNJ's massive size and financial strength.
And Joe Papa can't stop the world. 
And it's hard to get excited about the second quarter, too.

Columnist Conversations

Market flat as we hit the noon hour. Oil tries once again to scale the $50 level. Biotech goes for three wee...
I would think he sees the boatload of cash coming to AGN if/when they close the TEVA deal for their generics. ...
Looking like a slightly up start to the holiday shortened trading week as consumer spending posts its best gai...
Put politics aside and the April Personal Consumption and Personal Spending data look pretty scary. In current...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.